According to research reviewed by Gram, a 2026 study in Cellular Signalling found that a protein called QRICH1 appears to drive heart cell damage in diabetes by switching on the PDK4 gene. In diabetic mice, the drug vericiguat was reported to improve heart function, though these findings come from animal and lab work rather than human trials.
Diabetes can slowly weaken the heart muscle, but the exact chain of events has been unclear. According to research reviewed by Gram, a 2026 study in the journal Cellular Signalling identified a protein called QRICH1 that appears to switch on a gene called PDK4 when heart cells are exposed to high sugar and high fat. This combination seemed to damage the cells’ energy-producing structures, release fragments of their genetic material, and trigger inflammation and cell death. In mice with diabetes, heart function was reported to improve after treatment with vericiguat, a drug already approved for heart failure. These findings come from mouse and laboratory cell experiments, so they point toward possible new treatments rather than proven ones for people.
Key Statistics
A 2026 study published in Cellular Signalling reported that QRICH1, a protein that switches on the PDK4 gene, was markedly raised in diabetic heart tissue and in heart cells exposed to high sugar and fat.
In a 2026 mouse and cell study in Cellular Signalling, the heart drug vericiguat showed the strongest predicted binding to QRICH1 among the cardiovascular drugs screened, and it significantly improved heart function in diabetic mice.
A 2026 study in Cellular Signalling found that turning down the PDK4 gene partly reversed the cell death, weakened energy production, and inflammation caused by high QRICH1 levels in heart cells.
The Quick Take
- What they studied: The researchers wanted to know which control switch inside heart cells pushes them toward damage in diabetes, and whether an existing medicine could block that switch.
- Who participated: The study used mice fed a high-fat diet and given a drug that causes diabetes, plus heart muscle cells grown in the lab and exposed to high sugar and a fatty acid. The exact number of animals and cell samples was not stated in the summary.
- Key finding: The protein QRICH1 was found at much higher levels in diabetic heart tissue and in stressed heart cells. When it was turned up in cells, they showed more cell death, weaker energy production, and more inflammation, and these effects were partly reversed when the PDK4 gene was turned down.
- What it means for you: This research does not yet show that any food, supplement, or drug will protect your heart. It does suggest that managing blood sugar and fat intake matters for heart health, and that scientists may eventually develop treatments that target this pathway. Anyone with diabetes should keep following their doctor’s advice.
The Research Details
The researchers started by measuring QRICH1 in the hearts of mice that had been made diabetic in two ways. One group ate a high-fat diet, and another received a drug that damages insulin-producing cells, which is a common way to model type 2 diabetes in animals. They also measured QRICH1 in heart muscle cells that were exposed to high glucose and palmitic acid, a common saturated fat, to copy the stress that diabetes places on the heart.
Next, the team tested how QRICH1 affects the PDK4 gene. They used lab methods that check whether a protein physically attaches to a specific part of a gene and whether it switches that gene on. Then they changed QRICH1 levels in cells, turning it up or down, and also reduced PDK4 to see which effects depended on it. Finally, they used computer modeling and a lab test to screen existing cardiovascular drugs for ones that bind to QRICH1, and tested the best candidate, vericiguat, in diabetic mice.
This mix of animal work, cell experiments, and drug screening is a common early-stage strategy. It helps show how a process works step by step, but it cannot tell us how the same process would play out in the full complexity of a human body over many years.
Using several connected methods makes the findings more convincing than a single experiment would be. When a protein attaches to a gene, the gene becomes more active, and reducing that gene in cells partly undid the damage, the researchers were able to build a chain of cause and effect rather than just noticing a correlation. Testing a drug in living animals after screening it in the computer and the lab also moves the idea closer to a possible treatment.
Still, each step builds on models that are simplified versions of real human disease. Mice and cultured cells react differently from people, and a pathway that matters in a dish may matter less in a patient who has other health conditions and takes other medicines.
The study was published in a peer-reviewed scientific journal, which means outside experts reviewed the work before publication. The journal’s impact factor is a rough measure of how often its articles are cited, and it is moderate for this field. The summary does not report the number of animals or cell experiments, so readers cannot judge how many repeats supported each result. Because the work is preclinical, its reliability will depend on whether later studies reproduce it, especially in people.
What the Results Show
The central result was that QRICH1 was markedly raised in diabetic heart tissue and in heart cells exposed to high sugar and fat. This suggests the protein responds to the metabolic stress that diabetes creates, rather than being a random change that happens alongside it. The researchers reported that the protein directly attaches to the promoter region of PDK4, which is the part of a gene that controls when it is switched on, and that this boosts PDK4 production.
When QRICH1 was increased in heart cells, the cells showed more pyroptosis, a form of inflammatory cell death that causes surrounding tissue to become inflamed. The cells also had impaired mitochondrial respiration, meaning their energy-producing structures worked less efficiently. In addition, mitochondrial DNA, which is genetic material found inside the energy structures, leaked into the cell’s interior, where it can act as an alarm signal that triggers inflammation.
Many of these harmful effects were partially reversed when PDK4 was knocked down, which supports the idea that PDK4 is a key link in the chain. In the drug screen, vericiguat showed the strongest predicted binding to QRICH1 among the cardiovascular drugs tested. In diabetic mice, vericiguat was reported to significantly improve heart function, lower PDK4 levels, and restore a signaling protein called AKT, which helps cells respond normally to insulin and survive stress.
The study also reported that restoring AKT activity alongside the drug effects suggests that vericiguat may work partly by repairing the cell’s normal signaling rather than only acting on QRICH1. This is useful because it points to a broader set of mechanisms that a future treatment might target. The partial reversal of damage when PDK4 was reduced also suggests that PDK4 is one important piece of the pathway, though probably not the only one.
Diabetic heart disease, sometimes called diabetic cardiomyopathy, is known to involve shifts in how heart muscle burns fuel, along with inflammation and cell death. Previous research has linked PDK4 to changes in fuel use during fasting and diabetes, and mitochondrial damage has been widely studied in heart disease. This study adds QRICH1 as an upstream switch that connects those known pieces. Vericiguat is already used in people with certain types of heart failure, so testing it in this context is a logical next step, though its use for diabetic heart damage has not been established.
The most important limitation is that the work was done in mice and cultured cells, not in people. Animal models of diabetes do not perfectly match human disease, and results often shrink or change when moved to clinical trials. The summary also does not state how many animals or cell experiments were used, how the results were statistically analyzed, or whether the drug’s effects were measured over a long period. The drug screen used computer predictions, which are useful for ranking candidates but do not prove that a drug binds a target in the body. Finally, it remains unknown whether vericiguat would be safe or effective in people with diabetes, and whether it would need higher or lower doses for that purpose.
The Bottom Line
Based on this study alone, there is no recommendation to take vericiguat or any new supplement for diabetic heart disease. Confidence is low for direct human benefit because the evidence comes from animal and lab work. Confidence is moderate that QRICH1 and PDK4 are worth studying further as possible targets. Standard, proven steps still matter: keeping blood sugar in a healthy range, staying physically active, eating a heart-healthy diet, and taking prescribed medicines as directed.
People with diabetes, heart specialists, and researchers who study metabolic heart disease may find this work useful as a guide for future studies. Patients currently taking vericiguat for heart failure should not change their treatment based on this research, and anyone considering the drug for diabetes should talk with their doctor first. People without diabetes or heart concerns do not need to act on these findings.
Discoveries like this usually take many years to reach patients. The next steps would likely include more animal studies, safety checks, and eventually small human trials to see whether a treatment works and is safe. Realistic expectations are that any practical clinical use is probably years away and may never happen if the approach does not work in people.
Frequently Asked Questions
Does diabetes damage the heart, and how does it happen?
Yes, diabetes can weaken the heart muscle over time, a condition called diabetic cardiomyopathy. Research suggests high blood sugar and fat stress heart cells, damaging their energy structures and triggering inflammation and cell death, though the full process is still being mapped out.
What is QRICH1 and why does it matter for diabetic heart disease?
QRICH1 is a protein that acts as a switch controlling other genes. A 2026 study in Cellular Signalling reported it was raised in diabetic hearts and appeared to turn on PDK4, which contributed to heart cell damage in lab and mouse experiments.
Can vericiguat treat diabetic heart damage?
Vericiguat is approved for certain heart failure cases, and a 2026 mouse study found it improved heart function in diabetic animals. Human evidence for diabetic heart damage does not yet exist, so doctors do not currently use it for this purpose.
What can I do now to protect my heart if I have diabetes?
Keeping blood sugar in your target range, staying physically active, eating less saturated fat, and taking prescribed medicines are the best-supported steps today. Work with your doctor on a plan, since new drug research like this is still years from routine use.
Want to Apply This Research?
- Track fasting blood glucose or your daily average from a glucose meter, along with weekly resting heart rate and blood pressure readings. Log these numbers daily or several times a week so trends are easy to see.
- Use the app to set a daily goal of at least 150 minutes of moderate activity, such as brisk walking, and log it. Also track saturated fat intake from foods, since the study focused on high fat and high sugar conditions, and aim to replace some high-fat foods with vegetables, beans, or fish.
- Review your trends monthly and bring them to your healthcare provider at regular checkups. Over time, look for patterns in blood sugar, blood pressure, activity, and diet that match your energy levels and any symptoms such as shortness of breath or swelling. Treat the app as a record for your doctor, not as a substitute for medical testing or advice.
This article summarizes a laboratory and mouse study and is not medical advice. The research has not been tested in people, and no treatment, supplement, or drug change should be made based on it. Anyone with diabetes or heart concerns should consult a qualified healthcare provider before making decisions about medication, diet, or exercise.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.